Literature DB >> 31399876

Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity.

Robério Amorim de Almeida Pondé1,2,3.   

Abstract

Anti-HBs antibodies develop after natural infection with hepatitis B virus (HBV) or vaccination against this virus, as a result of activation of the human immune system by the HBV surface antigen (HBsAg). Anti-HBs-positive individuals are immunologically competent against HBV infection. This immunity is determined by the antibody levels in the bloodstream after resolution of natural infection or after vaccination. Anti-HBs antibody levels have been observed to decrease to below the protective level years after natural infection or vaccination, and there is reason to doubt that protective immunity to HBV is maintained after that. Factors that affect the maintenance of the anti-HBs antibody level in the bloodstream have been reported. Maintenance of immunity to HBV has been reported in anti-HBs negative individuals and those with detectable but low levels after natural infection or after vaccination. On the other hand, detection of anti-HBs antibodies without protective activity has also been observed. The presence or absence of anti-HBs antibodies in the context of HBV immunity has been the subject of extensive discussion and clinical, laboratory and epidemiological interest. These three scenarios of the anti-HBs response are discussed in this review article.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31399876     DOI: 10.1007/s00705-019-04369-9

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  5 in total

1.  De novo design of modular and tunable protein biosensors.

Authors:  Alfredo Quijano-Rubio; Hsien-Wei Yeh; Jooyoung Park; Hansol Lee; Robert A Langan; Scott E Boyken; Marc J Lajoie; Longxing Cao; Cameron M Chow; Marcos C Miranda; Jimin Wi; Hyo Jeong Hong; Lance Stewart; Byung-Ha Oh; David Baker
Journal:  Nature       Date:  2021-01-27       Impact factor: 49.962

2.  Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.

Authors:  Sonia Budroni; Francesca Buricchi; Andrea Cavallone; Patricia Bourguignon; Magalie Caubet; Vincent Dewar; Ugo D'Oro; Oretta Finco; Nathalie Garçon; Mohamed El Idrissi; Michel Janssens; Geert Leroux-Roels; Arnaud Marchant; Tino Schwarz; Pierre Van Damme; Gianfranco Volpini; Robbert van der Most; Arnaud M Didierlaurent; Wivine Burny
Journal:  NPJ Vaccines       Date:  2021-05-21       Impact factor: 7.344

3.  Cross-Sectional Association of Urinary Bisphenol A and Vaccine-Induced Immunity against Hepatitis B Virus: Data from the 2003-2014 National Health and Nutrition Examination Survey.

Authors:  Jun Young Uhm; Hyoung-Ryoul Kim
Journal:  Int J Environ Res Public Health       Date:  2022-01-19       Impact factor: 3.390

4.  Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia.

Authors:  Belaynew W Taye; Patricia C Valery; Paul J Clark
Journal:  J Viral Hepat       Date:  2022-07-02       Impact factor: 3.517

5.  Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24highCD38high Regulatory B Cells and Lower Levels of IL-10 Expression Compared to Responders.

Authors:  Nina Körber; Laureen Pohl; Birgit Weinberger; Beatrix Grubeck-Loebenstein; Andrea Wawer; Percy A Knolle; Hedwig Roggendorf; Ulrike Protzer; Tanja Bauer
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.